A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected Subjects

Inclusion Criteria: * Consent informed, written, signed and dated * Women or men aged 18 to 65 years inclusive * Carrier of L. loa microfilaremia * Body weight ≥ 40 kg in women and ≥ 45 kg in men; and less than 90 kg * In good health, as determined by medical questionnaire and general clinical examination * Absence of acute or chronic infection : Exclusion criteria * Participation in any study other than a purely observational study, within the 4 weeks preceding this study (determined by the theoretical date of the first administration of levamisole or placebo) * Any vaccination within 4 weeks previous to this study * Infection requiring treatment in the 10 days previous to this study, as determined by the anamnesis during the medical interview (e.g. pulmonary infection , digestive or skin infection; with or without antibiotic treatment) * Treatment with clozapine, phenothiazines, sulfasalazine, carbamazepine, synthetic antithyroid drugs, ticlopidine, cimetidine, and gold salts: whether it was long-term treatment, or treatment given as a single dose 10 days before the start of treatment for the clinical trial (precaution with regard to the risk of agranulocytosis of immuno-allergic or toxic origin) * Known immunosuppressive pathology (by self-report) * Past or present history of neurological (including epilepsy) or neuropsychiatric disease * History of agranulocytosis * Use of cocaine or other drugs of abuse in the 72 hours preceding administration of the trial treatment, …